These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33685323)

  • 21. Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma.
    Dissanayake S; Grothe B; Kaiser K
    Respir Med; 2012 Dec; 106 Suppl 1():S20-8. PubMed ID: 23273163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis.
    Maneechotesuwan K; Singh D; Fritscher LG; Dursunoglu N; P G A; Phansalkar A; Aggarwal B; Pizzichini E; Chorazy J; Burnett H
    Respir Med; 2022 Nov; 203():106993. PubMed ID: 36257125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
    Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    O'Shea O; Stovold E; Cates CJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD007694. PubMed ID: 33852162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.
    Singh D; Garcia G; Maneechotesuwan K; Daley-Yates P; Irusen E; Aggarwal B; Boucot I; Berend N
    Adv Ther; 2022 May; 39(5):1895-1914. PubMed ID: 35284999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M; Goldfrad C; Jacques L; Nishimura Y
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?
    Brattsand R; Selroos O
    Pulm Pharmacol Ther; 2022 Dec; 77():102167. PubMed ID: 36180011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
    Mehta N; Aggarwal B; Gogtay J; Abdool-Gaffar S
    Expert Opin Drug Deliv; 2015 Jun; 12(6):963-75. PubMed ID: 25429610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma.
    Mukhopadhyay A; Waked M; Gogtay J; Gaur V
    Respir Med; 2020; 170():106055. PubMed ID: 32843176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma.
    Tan RA; Corren J
    Drug Des Devel Ther; 2014; 8():1555-61. PubMed ID: 25328383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
    Price D; Hillyer EV
    Expert Rev Respir Med; 2014 Jun; 8(3):275-91. PubMed ID: 24802285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vilanterol and fluticasone furoate for asthma.
    Dwan K; Milan SJ; Bax L; Walters N; Powell C
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD010758. PubMed ID: 27582089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
    Płoszczuk A; Bosheva M; Spooner K; McIver T; Dissanayake S
    Ther Adv Respir Dis; 2018; 12():1753466618777924. PubMed ID: 29857783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial.
    Balki A; Balamurugan S; Bardapurkar S; Dalal S; Singh A; Singh BP; Vaidya A; Gogtay JA
    Pulm Pharmacol Ther; 2018 Feb; 48():28-36. PubMed ID: 28890299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
    Aalbers R
    Clin Drug Investig; 2010; 30(7):439-51. PubMed ID: 20528000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids.
    Kew KM; Beggs S; Ahmad S
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD011316. PubMed ID: 25997166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.